Systemic delivery of antagomirs during blood-brain barrier disruption is disease-modifying in experimental epilepsy
File Type:
PDFItem Type:
Journal ArticleDate:
2021Access:
openAccessCitation:
Reschke, C.R. and Silva, L.F.A. and Vangoor, V.R. and Rosso, M. and David, B. and Cavanagh, B.L. and Connolly, N.M.C. and Brennan, G.P. and Sanz-Rodriguez, A. and Mooney, C. and Batool, A. and Greene, C. and Brennan, M. and Conroy, R.M. and R??ber, T. and Prehn, J.H.M. and Campbell, M. and Pasterkamp, R.J. and Henshall, D.C., Systemic delivery of antagomirs during blood-brain barrier disruption is disease-modifying in experimental epilepsy, Molecular Therapy, 29, 6, 2021, 2041-2052Download Item:
1-s2.0-S1525001621000885-main.pdf (PDF) 2.841Mb
Abstract:
Oligonucleotide therapies offer precision treatments for a variety of neurological diseases, including epilepsy, but their deployment is hampered by the blood-brain barrier (BBB). Previous studies showed that intracerebroventricular injection of an antisense oligonucleotide (antagomir) targeting microRNA-134 (Ant-134) reduced evoked and spontaneous seizures in animal models of epilepsy. In this study, we used assays of serum protein and tracer extravasation to determine that BBB disruption occurring after status epilepticus in mice was sufficient to permit passage of systemically injected Ant-134 into the brain parenchyma. Intraperitoneal and intravenous injection of Ant-134 reached the hippocampus and blocked seizure-induced upregulation of miR-134. A single intraperitoneal injection of Ant-134 at 2 h after status epilepticus in mice resulted in potent suppression of spontaneous recurrent seizures, reaching a 99.5% reduction during recordings at 3 months. The duration of spontaneous seizures, when they occurred, was also reduced in Ant-134-treated mice. In vivo knockdown of LIM kinase-1 (Limk-1) increased seizure frequency in Ant-134-treated mice, implicating de-repression of Limk-1 in the antagomir mechanism. These studies indicate that systemic delivery of Ant-134 reaches the brain and produces long-lasting seizure-suppressive effects after systemic injection in mice when timed with BBB disruption and may be a clinically viable approach for this and other disease-modifying microRNA therapies.
Author's Homepage:
http://people.tcd.ie/campbem2http://people.tcd.ie/greenec9
Description:
PUBLISHEDcited By 3
Author: Campbell, Matthew; Greene, Chris
Type of material:
Journal ArticleCollections:
Series/Report no:
Molecular Therapy29
6
Availability:
Full text availableKeywords:
Status epilepticus, Noncoding RNA, Hippocampal sclerosis, Epileptogenesis, Chemoconvulsant, Antisense oligonucleotides, Antiepileptic drug, AntagomirsDOI:
http://dx.doi.org/10.1016/j.ymthe.2021.02.021Licences: